Showing papers in "Journal of Thrombosis and Haemostasis in 2008"

TL;DR: Pregnancy‐associated venous thrombosis was highly increased in carriers of factor V Leiden or the prothrombin 20210A mutation, and the risk was highest in the third trimester of pregnancy and during the first 6 weeks after delivery.

TL;DR: Development of PTS is the principal determinant of health‐related QOL 2’years after DVT and the need for effective prevention and treatment of the PTS is emphasized.

TL;DR: The combination of gestalt estimate of low suspicion for PE and PERC(−) reduces the probability of VTE to below 2% in about 20% of outpatients with suspected PE.

TL;DR: Antepartum immobilization, high BMI and reoperation on the indication of bleeding showed multiplicative effects on the risk of postnatal VT, and more attention should be paid to pregnant women of high BMI who are immobilized.

TL;DR: The probability of HIT antibodies (strong‐positive SRA result) inferred by a positive PF4‐dependent EIA varies considerably in relation to the magnitude of the EIA result, expressed as OD values.

TL;DR: The present narrative review updates the data available on the use of the various commercially available DD assays in the diagnostic approach of clinically suspected VTE in distinct patient populations or situations, including outpatients and inpatients, patients with cancer, older age, pregnancy, a suspected recurrent event, limited thrombus burden, and patients already on anticoagulant treatment.

TL;DR: PCC treatment serves as an effective rapid hemorrhage control resource in the emergency anticoagulant reversal setting and more widespread availability of PCC is warranted to ensure its benefits in appropriate patients.

TL;DR: In vivo, apixaban was effective in the prevention of experimental thrombosis at doses that preserve hemostasis in rabbits and potent and selective, with a Ki of 0.08 nm for human FXa.

TL;DR: DU‐176b is a more potent and selective FXa inhibitor with high oral bioavailability compared with its prototype, DX‐9065a, and represents a promising new anticoagulant for the prophylaxis and treatment of thromboembolic diseases.

TL;DR: TF was measured in samples obtained from patients with locally advanced or metastatic pancreatic cancer enrolled in a prospective trial conducted by the University of Rochester Community Clinical Oncology Program and hypothesized that elevated circulating levels of TF would be associated with development of VTE in pancreaticcancer.

TL;DR: The attractive fixed‐dose regimen of this compound may meet the demand to simplify anticoagulant treatment in patients with established venous thromboembolism and warrant further evaluation of apixaban in phase III studies.

TL;DR: The low likelihood of patients with cAF in general practice remaining on treatment long‐term indicates that not all benefits as observed in clinical trials may be achieved in usual clinical practice.

TL;DR: Approximately 3% of lung cancer patients developed VTE within 2’years, and the diagnosis of VTE was associated with a higher risk of death within2 years for NSCLC and SCLC.

TL;DR: Detectable levels of TF‐dependent PCA and thrombin‐antithrombin complex were found in cell‐free plasmas from mice growing pancreatic human tumors, suggesting that circulating tumor‐derived TF causes coagulation activation in vivo.

TL;DR: The Condensed MCMDM‐1VWD Bleeding Questionnaire is an efficient, effective tool in the evaluation of patients for VWD.

TL;DR: This review will briefly summarize some of the mechanisms of cooperativity between platelets and the immune system, focusing in part on a recently uncovered novel pathway for bacterial trapping in the vasculature.

TL;DR: Women, obese patients, patients with proximal DVT and those with varicose veins have an increased risk of PTS, whereas the elderly appeared to have a decreased risk, despite the widespread use of elastic compression stockings.

TL;DR: A high rate of unprovoked recurrent venousThrombin generation in patients presenting with a first episode of venous thrombosis and a high ETP is demonstrated in this study.

TL;DR: The measurement of TG helps to identify patients at higher risk of VTE recurrence and the increased risk may be better appreciated if the test is performed in the presence of thrombomodulin.

TL;DR: To evaluate the proportion of misclassification of patients historically diagnosed with type 1 VWD using detailed analysis of the VWF multimer structure, the finding that even slightly aberrant multimers are highly predictive for the presence of VWF mutations is supported.

TL;DR: Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/ cotranslocation and a new VKORC1 allelic variant in a patient with partial resistance to acenocoumarol and phenprocoumon.

TL;DR: Wild‐type murine platelets adhered and aggregated on collagen in a biphasic shear‐dependent manner with increased deposition from 100 to 400’s−1, but decreased deposition at 1000 s+1, while PAR4 signaling enhances aggregate stability by mechanisms independent of other thrombin‐dependent pathways such as fibrin formation.

TL;DR: Both persistent stress and low occupational class were independently related to future pulmonary embolism.

TL;DR: Early diagnosis of AVWS is difficult, due to lack of sensitivity of the tests used, and a substantial number of patients present with normal or increased test results, emphasizing the importance of multimer analysis in all patients with suspected AVWS.

TL;DR: In this article, the authors evaluated the pharmacokinetics, efficacy and safety of a plasma-free recombinant FVIII concentrate, ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method, rAHF-PFM], in children < 6 years of age with severe hemophilia.

TL;DR: The findings show that proplatelet formation in human megakaryocytes undergoes a complex spatio‐temporal regulation orchestrated by adhesive proteins, GPIb‐IX‐V and myosin IIA.

TL;DR: It was demonstrated that these leukocyte functions were dependent on C3 activation and signaling via C5a, as this expression could be inhibited by compstatin and by a C5 aR antagonist.

TL;DR: Adjustment of PRP for platelet count does not provide any advantage and therefore the time‐consuming process of Platelet count adjustment is not necessary, whereas late aggregation using ADP 2 μm in non‐adjusted PRP offers the best discrimination between clopidogrel‐treated patients and healthy controls.

TL;DR: The physiological functions of these kinases in hemostasis and thrombosis as revealed by various technical approaches are summarized and discussed.

TL;DR: Thrombophilia testing in patients with a first VT does not reduce the incidence of recurrence in clinical practice, and the odds ratio for recurrent thrombosis remained unchanged.